This is an interventional, pilot, multicenter, randomized, open-label, phase 2 study,
enrolling patients with COVID-19 disease. One-month rate of entering the critical stage
(either a. Respiratory failure occurs and requires mechanical ventilation; b. Patients
combined with other organ failure need ICU monitoring and treatment; c. Death) is the primary
endpoint.